Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older

NCT04405076 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

660

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2

Interventions

BIOLOGICAL: Biological: mRNA-1273
BIOLOGICAL: Placebo
BIOLOGICAL: mRNA-1273.351

Sponsor

ModernaTX, Inc.

Collaborators

[object Object]